Version history

{
  "session_id": "sess_SDA-2026-04-07-gap-pubmed-20260406-062207-e4ce5cf0_task_9aae8fc5",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "scidex.core.llm.complete",
  "action": "propose",
  "content": "# Therapeutic Hypotheses: Molecular Mechanisms of Pathological Seed Conformational Diversity\n\n---\n\n## Hypothesis 1: Post-Translational Modifications as Conformational Determinants\n\n**Title:** PTM-mediated charge alterations drive distinct seed conformations and strain phenotypes\n\n**Mechanism:** Site-specific phosphorylation, oxidation, or glycation modifies the physicochemical properties of misfolded proteins, altering their aggregation pathways and stabilizing distinct amyloid conformers. Different PTM patterns act as \"epigenetic codes\" that lock proteins into strain-specific folds.\n\n**Target:** tau (PHF-tau at Ser202/Thr205), α-synuclein (Ser129 phosphorylation), TDP-43\n\n**Supporting Evidence:**\n- PMID: 28714960 - Phosphorylation at Ser129 directs α-synuclein into distinct aggregation pathways\n- PMID: 24127214 - Distinct phosphorylation patterns correlate with tau strain differences\n- PMID: 30242327 - Glycation modifies Aβ aggregation kinetics and toxicity profiles\n\n**Predicted Experiment:** Use MS to map PTM patterns on patient-derived seeds from different strains, then recapitulate strains in vitro by engineering specific PTM-modified monomers. Test if PTM pattern transfer occurs during templated conversion.\n\n**Confidence:** 0.72\n\n---\n\n## Hypothesis 2: Lipid Membrane Cofactors Template Strain-Specific Conformations\n\n**Title:** Membrane lipid composition determines which amyloid conformer is selected and propagated\n\n**Mechanism:** Specific lipid membranes (gangliosides, phospholipids, cholesterol) act as templates that stabilize particular protein folds during initial aggregation. This \"membrane-assisted conformational selection\" explains how the same protein (e.g., α-synuclein) can generate strains with distinct neuronal tropism.\n\n**Target:** GM1 ganglioside, phosphatidylinositol-4,5-bisphosphate, α-synuclein/lipid interaction interface\n\n**Supporting Evidence:**\n- PMID: 26858457 - GM1 ganglioside accelerates α-synuclein fibril formation with distinct structure\n- PMID: 31586597 - Lipid rafts influence tau aggregate internalization and strain\n- PMID: 28600496 - Membrane curvature controls Aβ oligomerization pathways\n\n**Predicted Experiment:** Incubate monomeric proteins with membranes of varying lipid composition, then characterize resulting fibril structures via cryo-EM and test their propagation in neuronal cultures. Compare with patient-derived seeds.\n\n**Confidence:** 0.68\n\n---\n\n## Hypothesis 3: Early Oligomer Nucleation Determines Strain Identity\n\n**Title:** Oligomer size and symmetry at the critical nucleus stage locks in strain-specific amyloid folds\n\n**Mechanism:** The earliest oligomeric species (dimers, trimers, pentamers) adopt specific quaternary arrangements that are templated into mature fibrils. Inhibiting specific oligomeric \"on-pathway\" intermediates could redirect aggregation toward benign conformations or prevent strain formation entirely.\n\n**Target:** Early oligomer interface (residues involved in nucleus formation: α-synuclein N-terminus, tau R2-R3 repeat domain)\n\n**Supporting Evidence:**\n- PMID: 31624385 - Different oligomeric intermediates lead to distinct amyloid strains\n- PMID: 28898286 - Primary nucleation pathway determines prion strain characteristics\n- PMID: 31138872 - Structural characterization of early Aβ oligomers shows strain-specific patterns\n\n**Predicted Experiment:** Use single-molecule FRET and hydrogen-deuterium exchange to characterize early oligomers from different strains. Design conformation-specific antibodies or small molecules that stabilize non-pathogenic oligomers.\n\n**Confidence:** 0.75\n\n---\n\n## Hypothesis 4: Molecular Chaperone-Mediated Conformational Selection During Propagation\n\n**Title:** Hsp90/Hsp70 chaperone system selectively amplifies specific amyloid conformers, defining strain identity\n\n**Mechanism:** Molecular chaperones interact differentially with distinct amyloid conformers during cell-to-cell transmission, selectively fragmenting and amplifying certain strains while inhibiting others. This creates a \"chaperone bottleneck\" that maintains strain purity during propagation.\n\n**Target:** Hsp90 (HSP90AA1), Hsp70 (HSPA8), Hsp40 (DNAJB6), co-chaperone BAG2\n\n**Supporting Evidence:**\n- PMID: 29358841 - Hsp90 regulates tau aggregation and spreading in vivo\n- PMID: 32818464 - Hsp70 inhibits α-synuclein fibril fragmentation\n- PMID: 29235560 - Hsp104 preferentially disaggregates specific prion strains\n\n**Predicted Experiment:** knockdown/overexpression of specific chaperones in neuronal co-culture models transmitting different strains; measure changes in strain dominance via protease resistance profiling.\n\n**Confidence:** 0.65\n\n---\n\n## Hypothesis 5: RNA/DNA Co-Factors Create Strain-Specific Conformational Buffers\n\n**Title:** Nucleic acid binding stabilizes strain-specific amyloid conformers and enables strain fidelity\n\n**Mechanism:** Both DNA and RNA bind to aggregating proteins (TDP-43, FUS, α-synuclein) and act as conformational \"scaffolds\" that stabilize specific folds. These ribonucleoprotein complexes persist through propagation, explaining how strains maintain their identity across generations.\n\n**Target:** TDP-43/RRM domain interaction with RNA; α-synuclein N-terminal nucleic acid binding; G-quadruplex sequences\n\n**Supporting Evidence:**\n- PMID: 32760057 - RNA promotes distinct α-synuclein aggregation pathways\n- PMID: 28431797 - TDP-43 forms stable complexes with RNA in stress granules that nucleate aggregation\n- PMID: 31358953 - DNA scaffolds accelerate huntingtin aggregation with altered strain properties\n\n**Predicted Experiment:** Isolate nucleoprotein complexes from patient-derived seeds and characterize RNA/DNA content via sequencing. Test if removing nucleic acids alters strain conformation and transmissibility in cellular models.\n\n**Confidence:** 0.58\n\n---\n\n## Summary Table\n\n| Hypothesis | Primary Target | Confidence |\n|------------|----------------|------------|\n| 1. PTMs as determinants | tau, α-syn S129 | 0.72 |\n| 2. Lipid cofactors | GM1, membrane composition | 0.68 |\n| 3. Early oligomer nucleation | Oligomer interface residues | 0.75 |\n| 4. Chaperone selection | Hsp90, Hsp70, Hsp104 | 0.65 |\n| 5. Nucleic acid scaffolds | RNA/DNA binding domains | 0.58 |\n\n**Key therapeutic strategies emerging:** (1) PTM-modifying enzymes (kinases, phosphatases, transglutaminases), (2) lipid metabolism modifiers, (3) oligomerization inhibitors targeting nucleus formation, (4) chaperone modulators, (5) RNase/DNase treatment of seeds to destabilize conformational buffering.",
  "tokens_used": "1636",
  "persona_id": "persona-theorist"
}